Trailing Twelve Months Revenue Growth: BioLineRx Corporation (BLRX)

Public company logo of biolinerx.com (BLRX)

The percentage change in sales over the last 12 months compared to the previous 12 months correlates with the automation of laboratory data collection, and this metric equals -92.00. BioLineRx Ltd. (BLRX) bases its business development on attracting Israeli scientists through stock option programs and the recognition of their work. Commercial success is driven by the expansion of US distribution for Aphexda and strict compliance with FDA regulations, which limits access for third-party players.

BioLineRx Ltd. (BLRX): Revenue Growth YoY (Last 12 Months) from 02/11/2024 to 11/15/2026

BioLineRx Ltd. - analytical breakdowns and key metrics (BLRX)

- stock price and consensus target price:
Price Chart BioLineRx Corporation|BLRX - Price Target Chart
- company stock exchange capitalization indicators:
Market Value BioLineRx Ltd.|BLRX - Enterprise Value
- book capitalization data:
Book Value of One Share BioLineRx|BLRX - Company Net Assets|Market-to-Book Ratio biolinerx.com|BLRX - Cumulative Company Assets
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio BioLineRx Ltd.|BLRX - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio BioLineRx|BLRX - Company Aggregate Debts|Debt to Net Assets Ratio BioLineRx Ltd.|BLRX - Company Long-Term Debts|Short-Term Debt BioLineRx|Intermediate Coverage Ratio biolinerx.com
- net income and valuation ratios data:
BLRX - Net Profit|Projected Future Earnings BioLineRx Ltd.|BLRX - Price to Earnings Ratio|Price to Expected Earnings Ratio BioLineRx|BLRX - Price/Earnings to Growth Multiple|Company Value to EBITDA BioLineRx Ltd.|BLRX - Operating profit EBITDA|Earnings per share for the last twelve months BioLineRx|BLRX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months biolinerx.com|BLRX - Earnings per share growth in current year|Expected net earnings per share growth next year BioLineRx Ltd.
- sales and revenue indicators:
BLRX - Company Revenue|Company Projected Revenue BioLineRx Corp|BLRX - P/S Multiple|Market Cap to Expected Sales Ratio BioLineRx Ltd|BLRX - Sales Growth YoY (Last Twelve Months)
Summary company analytics:BioLineRx Corp
Brand item of BioLineRx Corporation

This indicator measures the percentage change in revenue over the last four quarters compared to the same interval of the previous year. By analyzing the YoY revenue growth over a rolling 12-month period on GURU.Markets, an investor assesses the sustainability of market demand. The mathematical calculation eliminates seasonality, capturing the real pace of business expansion. For BioLineRx Ltd. (BLRX), this metric reflects the effectiveness of commercializing approved therapeutic drugs. An increase in this indicator confirms the successful implementation of the innovative R&D pipeline in oncology.

Who BioLineRx Ltd. competes with

Incyte Pharma - Sales Growth YoY (Last Twelve Months)|HUTCHMED Corp - Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth Nuvation Bio Inc.|DAWN: Sales Growth YoY (TTM)|Revenue Growth Rate YoY (Last Twelve Months) Monopar Pharma MNPR|Revenue Growth YoY (Last 12 Months) INBX|Trailing Twelve Months Revenue Growth I-Mab Biopharma IMAB|Revenue Growth YoY (Last 12 Months) FENC (Fennec Pharmaceuticals)|HRTX (Heron Therapeutics Inc) - Revenue Dynamics YoY (Last Twelve Months)|Nuvectis Pharma, Inc. - Revenue Growth YoY (Last 12 Months)|Revenue Change YoY (Last 12 Months) CHRS (Coherus BioSciences)|Corbus Pharma - Sales Growth YoY (TTM)|Revenue Dynamics YoY (Last Twelve Months) CRDF (cardiffoncology.com)|BYSI: Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth BioAtla Corp (BCAB)|Sales Growth YoY (Last Twelve Months) Lixte Biotechnology Holdings, Inc.|CTXR: Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (TTM) CLRB|Sales Growth YoY (TTM) Can-Fite (CANF)|Sales Growth YoY (Last Twelve Months) Aprea Therapeutics Inc. APRE|KZIA (kaziatherapeutics.com) - Trailing Twelve Months Sales Growth|SLXN: Revenue Growth YoY (Last 12 Months)|Trailing Twelve Months Revenue Growth NuCana|CMRX: Sales Growth YoY (TTM)|Revenue Growth YoY (Last 12 Months) Cyclacel Pharmaceuticals|GTHX (g1therapeutics.com) - Sales Growth YoY (TTM)|KRON: Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (Last Twelve Months) Kintara (KTRA)|Revenue Growth YoY (Last 12 Months) Oncternal ONCT|Portage Biotech - Revenue Growth YoY (Last 12 Months)